

To do so, a public education and awareness campaign will be launched to bring about changes in beliefs and social norms among target audiences (consumers: women aged 40–60, healthcare practitioners: nurse practitioners and physician assistants)

that CFS is a diagnosable and treatable physical illness. Although considerable research will be done to ensure that campaign themes, messages, and materials are effective, there is no way to test the impact of the campaign on the target audience other than to conduct baseline

and follow-up surveys. These surveys will measure not only the level of awareness created by the campaign, but will measure change in key knowledge, attitudes and beliefs about CFS among the target audiences. There is no cost to respondents other than their time.

ESTIMATE OF ANNUALIZED BURDEN HOURS

Respondents	Instrument	Number of respondents	Number of responses per respondent	Response burden per respondent (in hours)	Total annual burden (in hours)
Consumers (Women, 40–60 years of age)	Pre-program survey	400	1	10/60	67
Consumers (Women, 40–60 years of age)	Post-program survey	400	1	10/60	67
Physician Assistants	Pre-program survey	200	1	10/60	33
Physician Assistants	Post-program survey	200	1	10/60	33
Nurse Practitioners	Pre-program survey	200	1	10/60	33
Nurse Practitioners	Post-program survey	200	1	10/60	33
Total	266

Dated: October 4, 2005.
Betsy Dunaway,
Acting Reports Clearance Officer, Centers for Disease Control and Prevention.
 [FR Doc. 05–20323 Filed 10–7–05; 8:45 am]
 BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
 [Docket No. 2004N–0526]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Guidance for Industry: Fast Track Drug Development Programs—Designation, Development, and Application Review

AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled “Guidance for Industry: Fast Track Drug Development Programs—Designation, Development, and Application Review” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of June 7, 2005 (70 FR 33177), the agency announced that the proposed information collection had been submitted to OMB for review and

clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0389. The approval expires on August 31, 2008. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: October 3, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
 [FR Doc. 05–20305 Filed 10–7–05; 8:45 am]
 BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
 [Docket No. 2005N–0083]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling, Revocation and Suspension, and Forms FDA 356h and 2567

AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled “General Licensing Provisions: Biologics License Application, Changes

to an Approved Application, Labeling, Revocation and Suspension, and Forms FDA 356h and 2567” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of July 21, 2005 (70 FR 42068), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0338. The approval expires on September 30, 2008. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: October 3, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
 [FR Doc. 05–20306 Filed 10–7–05; 8:45 am]
 BILLING CODE 4160–01–S